. [82] to assess the efficacy, safety and tolerability of Cannabidiol being an adjunct therapy coupled with anti-epileptic medicines on the clients struggling from tuberous sclerosis intricate whose most common neurological symptom is epilepsy. In this medical trial study, immediately after treatment with Cannabidiol, responder fee with the patient